Xendo CEO André van de Sande moderating a session about Strategies for growth for Life Sciences companies at the recent Dutch Biotech Event. Synthon and Merus shared their insights about their successful company strategies.
Harm Hermsen holds a Ph.D. in Biochemistry. Harm has worked for the office for Genetically Modified Organisms (GMO office) at the Dutch National Institute for Public Health and the Environment (RIVM). For a few
Xendo offers industry seasoned CMC project managers and over 100 pharma and biotech professionals in biological sciences, biotech, and small molecule development. We cover the areas of manufacturing, analytics, quality assurance, engineering and regulatory affairs. Xendo has experience with the development of MAbs, recombinant proteins, vaccines, gene and cell therapy products, and small molecules. We can provide you with a product development roadmap and successfully guide your product development to Clinical Proof-of-Concept and to the market.
For your medical device
CASE STUDY: Monoclonal Antibody Development
Schipholweg 73 – 75
P.O. Box 255, 2300 AG Leiden, The Netherlands
tel +31 (0)71 524 40 00 - fax +31 (0)71 524 40 01